Business Context and Reporting Period
Company: TECHNE Corporation (BIO-TECHNE Corp)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended June 30, 2007
Business Overview: The Company develops and manufactures biotechnology products (cytokines, antibodies, assay kits) and hematology calibrators and controls. Operations are conducted through three reportable segments: Biotechnology (domestic and global), R&D Systems Europe, and Hematology. In late fiscal 2007, the Company established a subsidiary in Shanghai, China (R&D China) to distribute products in the region. The Company acquired Fortron BioScience and BiosPacific in July 2005, which were fully integrated into operations by the end of the reporting period.
Key Financial Metrics
| Metric (in thousands) | Fiscal 2007 | Fiscal 2006 | Fiscal 2005 |
|---|---|---|---|
| Net Sales | $223,482 | $202,617 | $178,652 |
| Gross Margin | $176,815 | $156,899 | $141,839 |
| Gross Margin % | 79.1% | 77.4% | 79.4% |
| Operating Income | $124,154 | $108,503 | $97,763 |
| Net Earnings | $85,111 | $73,351 | $66,132 |
| Diluted EPS | $2.15 | $1.85 | $1.62 |
| Operating Cash Flow | $90,503 | $85,589 | $74,433 |
| Total Assets | $454,844 | $370,512 | $295,263 |
| Long-Term Debt | $0 | $12,198 | $13,378 |
| Cash & Investments | $256,200 | $186,500 | $164,774 |
Note: Cash & Investments figure for 2007 combines Cash, cash equivalents ($135.5M) and Short-term/Long-term available-for-sale investments ($120.7M) as reported in the Liquidity section.
Material Changes vs. Prior Period
- Revenue Growth: Consolidated net sales increased 10.3% to $223.5 million. The Biotechnology segment drove growth with a 9.1% increase, while R&D Europe sales rose 16.6% (partially due to favorable currency exchange rates). Hematology sales declined slightly by 1.0%.
- Profitability: Net earnings increased 16.0% to $85.1 million. Gross margin percentage improved to 79.1% from 77.4%, aided by reduced purchase accounting impacts from prior acquisitions and favorable foreign exchange rates.
- Debt Reduction: The Company paid off its entire mortgage debt in October 2006. As of June 30, 2007, the Company had no long-term debt outstanding, only an unsecured line of credit of $0.8 million with no borrowings.
- Investments: The Company made significant equity investments in fiscal 2007, including $7.2 million in Nephromics LLC and an additional $700,000 in Hemerus Medical, LLC. Total investments in unconsolidated entities rose to $24.2 million.
Outlook, Risks, and Management Commentary
- Guidance & Outlook: Management expects to meet future cash requirements through current funds and operating cash flow. Capital expenditures for fiscal 2008 are estimated at $3.6 million for equipment and $3.0 million for facility construction completion. No specific revenue guidance was provided in the text.
- Key Risks:
- Research Funding: Revenue is sensitive to spending by pharmaceutical companies and government funding for university research (e.g., NIH).
- Currency Fluctuation: Approximately 25% of sales are in foreign currencies (primarily British Pound). A 10% change in the GBP/USD rate could impact operating income by approximately $1.8 million.
- Patent Litigation: The Company is involved in a patent infringement lawsuit filed by Streck Laboratories regarding hematology controls. Management does not believe the outcome will materially impact financial statements.
- Investment Impairment: Equity investments in early-stage companies (Nephromics, Hemerus, ChemoCentryx) carry the risk of impairment if FDA clearance is not obtained or funding is unavailable.
- Unusual Items: Interest expense in fiscal 2007 included a $651,000 prepayment penalty and $78,000 in unamortized fees related to the early payoff of the mortgage debt.
Investor Verification Checklist
- Debt Status: Confirm the Company remains debt-free regarding long-term obligations and monitor the status of the $0.8 million line of credit.
- Equity Investments: Review the progress of Nephromics and Hemerus regarding FDA clearance and funding needs, as impairment could impact earnings.
- Patent Litigation: Monitor the status of the Streck Laboratories lawsuit and any potential interference proceedings with the USPTO.
- China Expansion: Verify the operational status and revenue contribution of the new R&D China subsidiary in Shanghai.
- Inventory Valuation: Note the $13.9 million reserve for protein and antibody inventory based on a two-year usage forecast; monitor for changes in this policy or forecast.